A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease (original) (raw)
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
Peter Lewitt
Movement Disorders, 2004
View PDFchevron_right
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
F. Stocchi
Movement Disorders, 2008
View PDFchevron_right
A Controlled Trial of Rasagiline in Early Parkinson Disease
C Allen
Archives of Neurology, 2002
View PDFchevron_right
Rasagiline improves quality of life in patients with early Parkinson's disease
Carrie Irvine
Movement Disorders, 2006
View PDFchevron_right
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
Cheryl Fitzer-Attas
Movement Disorders, 2009
View PDFchevron_right
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Paul Feigin
The Lancet Neurology, 2011
View PDFchevron_right
Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease
Rainer Apfel
European Journal of Neurology, 2010
View PDFchevron_right
Randomized, Controlled Trial of Rasagiline as an Add-on to Dopamine Agonists in Parkinson's Disease
Eli Eyal
View PDFchevron_right
Use of the Unified Parkinson’s Disease Rating Scale Activities of Daily Living Subscale to Assess Response to Rasagiline in Early Parkinson’s Disease
Daniel Kremens
US Neurology, 2011
View PDFchevron_right
Rapid onset of efficacy of rasagiline in early Parkinson’s disease
Angelo Antonini
Neurological Sciences, 2013
View PDFchevron_right
Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
Michele Pistacchi
Neurology and Therapy, 2013
View PDFchevron_right
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
Eli Eyal
JAMA Neurology, 2015
View PDFchevron_right
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients
Giuseppe Meco
European journal of neurology : the official journal of the European Federation of Neurological Societies, 2015
View PDFchevron_right
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
Olivier Rascol
The Lancet, 2005
View PDFchevron_right
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
Benzi Kluger
Movement Disorders, 2015
View PDFchevron_right
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study
Anna Zecchinelli
Journal of neurology, 2017
View PDFchevron_right
Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa
Amos Korczyn
Clinical Neuropharmacology, 2000
View PDFchevron_right
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability
Eli Eyal
2015
View PDFchevron_right
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
Görsev Yener, Hasmet A. Hanagasi
Movement Disorders, 2011
View PDFchevron_right
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
marie armentero
Experimental Neurology, 2004
View PDFchevron_right
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack Chen
Clinical therapeutics, 2007
View PDFchevron_right
Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
Ján Benetin
Biomedical Papers, 2016
View PDFchevron_right
Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy
Philip Lazarovici
Therapeutics and Clinical Risk Management, 2007
View PDFchevron_right
Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting
Alan Haycox
Drugs & Aging, 2009
View PDFchevron_right